Background: Operational tolerance is an alternative to lifelong immunosuppression after transplantation. One strategy to achieve tolerance is by T regulatory cells. Safety and feasibility of a T regulatory type 1 (Tr1)-cell-based therapy to prevent graft versus host disease in patients with hematological malignancies has been already proven. We are now planning to perform a Tr1-cell-based therapy after kidney transplantation.
Background
Circulating T regulatory type 1 (Tr1) cells with an alloantigen-specific regulatory function have been consistently associated with operational tolerance after transplantation [1] . Alloantigen-specific Tr1 cells can be induced in vitro in the presence of exogenous IL-10 or by tolerogenic IL-10-producing dendritic cells (DC-10) and they are hyporesponsive (anergic) to the alloantigen used for their generation [2, 3] . These IL-10-anergized T cells have been tested as medicinal product in a proofof-concept trial in patients undergoing haploidentical hematopoietic stem cell transplantation (HSCT) to provide immune reconstitution in the absence of severe graft versus host disease (GvHD) (the ALT-TEN trial) [4] .
The ONE Study-a European Commission FP7-funded consortium-aims to test several distinct haematopoietic immunoregulatory cells as therapies after kidney transplantation from living donors by initiating a series Mfarrej et al. J Transl Med (2017) 15:40 of independent clinical trials based on the same general design [5] . Our group participates in this consortium to test donor-specific Tr1 cells. The ALT-TEN trial already performed was certainly instrumental although the know-how that was developed in this first clinical experience did not necessarily allow performing The ONE Study faster and more efficiently. We overcame the first hurdle of tailoring the Tr1-cell generation protocol to patients on dialysis, yet only at a lab-scale [6] . In this study, we aimed at: (1) defining a reproducible and clinical-grade compatible protocol for the generation of a Tr1-cell-enriched medicinal product for kidney transplant recipients, (2) characterizing the final cell product, and (3) testing the sensitivity of circulating Tr1 cells to immunosuppressive therapy to determine the ideal timing of the medicinal product infusion.
Methods

Healthy donors and patients
Peripheral blood, buffy coat or leukapheresis were obtained from healthy donors or renal transplant recipients enrolled in The ONE Study Reference Group Trial (i.e., control group in which patients were treated with standard immunosuppressive therapy) (NCT01656135) after written informed consent in accordance with the Declaration of Helsinki under the protocol approved by the San Raffaele Hospital's Ethics Committee (IRB #OSR-TheOne).
Generation and characterization of dendritic cells
Peripheral blood mononuclear cells (PBMC) were isolated by density-gradient centrifugation on Lymphoprep (Axis-Shield, Oslo, Norway). IL-10-producing dendritic cells (DC-10) and mature DC (mDC) were generated from healthy donors [7] . Monocytes were isolated by harvesting the adherent fraction of PBMC or by selection with CD14 + microbeads using the AutoMACS system (Miltenyi Biotec, Bergisch Gladbach, Germany) and following manufacturer's instructions. Monocytes were cultured with 10 ng/ml rhIL-4 (GMP-grade, Miltenyi Biotec) and 100 ng/ml rhGM-CSF (GMP-grade, Miltenyi Biotec) for 7 days in the presence (DC-10) or absence (mDC) of 10 ng/ml rhIL-10 (GMP-grade, CellGenix GmbH, Freiburg, Germany). The culture medium was supplemented with GMP-grade fetal bovine serum (FBS) (Lonza, Basel, Switzerland) or GMP-grade human AB sera (Lonza). mDC were matured during the last 2 days of culture with 5 µg/ml of rMPL-A (GMP-grade, Invivogen, Toulouse, France). At the end of the 7-day cultures, DC-10 and mDC were harvested and irradiated at 60 Gy with a Cs137 source Biobeam 2000 irradiator (Gamma-Service Medical GmbH, Leipzig, Germany). DC-10 yield was measured as: 100× [no. of generated DC-10 cells/no. of plated cells].
Supernatants were collected 48 h after culturing DC-10 in the presence or absence of stimulation by lipopolysaccharide (LPS) from Escherichia coli (5μg/ml, Sigma Chemicals, St. Louis, MO). IL-10 released into the supernatant was quantified by ELISA (BD Pharmingen, San Diego, CA). The detection limit of IL-10 was 15 pg/ml.
Generation and characterization of Tr1-cell enriched product: T 10 cells
CD4 + T cells were isolated from donors different from those used to generate DC by CD4 + microbeads using the AutoMACS system (Miltenyi Biotec) following manufacturer's instructions. Purified CD4 + T cells were cultured with irradiated allogeneic DC-10 or mDC (10:1 ratio) in the presence or absence of exogenous rhIL-10 (10 ng/ml) for 10 days to generate T 10 or control Tm cells, respectively ( Fig. 1 ) [8] . T 10 -cell yield was measured as: 100× [no. of T 10 cells generated/no. CD4 + T cells plated]. To test the generation of donor-specific anergic T cells, T 10 and Tm cells were cultured with the original-donor mDC (previously frozen) and cell proliferation was monitored via 3 H-thymidine (PerkinElmer, Waltham, MA, USA) incorporation (counts per min, cpm) in the last 16-18 h of a 3-day culture. Anergy was calculated as: cpm [(T 10 + mDC)/(Tm + mDC)] ×100. Supernatants were collected before 3 H-thymidine addition and quantification of IFNγ or IL-10 by ELISA (BD Pharmingen) was performed. The detection limit of IFN-γ was 15 pg/ml. Ability of T 10 cells to suppress the proliferation of autologous CD4 + T cells upon donor or third party mDC stimulation was assessed by 3 H-thymidine incorporation in the last 16-18 h of a 5-day culture.
Flow cytometry
The immune phenotype of in vitro generated DC, T 10 and Tm cells was tested by flow cytometry as previously described [8] . The TCR Vβ repertoire was determined with the IOTest ® Beta Mark TCR V beta Repertoire Kit (Beckman Coulter, Inc, Brea, CA, USA) following manufacturer's instructions.
Cells were analyzed with the BD FACS Canto II (Beckton Dickinson, San Jose, CA, USA) within few hours after staining. Data was analyzed using FCS 3.0 (DeNovo Instruments, Los Angeles, CA, USA).
Dual IFNγ/IL-10 ELISPOT
Dual IFNγ/IL-10 ELISPOT (Diaclone, Besancon, France) was performed according to manufacturer's instructions with a slight modification: visualization of IL-10 was performed using Vector Blue Alkaline Phosphatase substrate kit (Vector Labs, Burlingame, CA, USA) and the A.EL.VIS 4-Plate ELISPOT Reader (A.EL.VIS GmbH, Hannover, Germany) was used. Analysis was performed using ImageJ (version 1.48, NIH, USA) to quantify IFNγproducing cells (red spots), IL-10-producing cells (blue spots) or dual IFNγ/IL-10-producing cells (purple spots).
Transcript analysis of purified Tr1 cells
Peripheral blood was collected and PBMC were frozen from patients enrolled in The ONE Study Reference Group Trial at our center at the following time points: 4-weeks pre-transplant, 8-36-and 60-weeks posttransplant. PBMC were thawed and Tr1-cell sorting was performed using MoFlo Legacy Cell Sorter (Beckman Coulter, Indianapolis, IN, USA). To verify the expression of anti-inflammatory genes characteristic of Tr1 cells (as previously described [1] ) and pro-inflammatory genes characteristic of T effector cells (i.e., il-17a, il-1b, tnf, il-6 and ifnγ), QuantiGene 15-plex assay (Affymetrix, Santa Clara, CA, USA) was performed following manufacturer's instructions. Mean fluorescence intensity from the measured beads per gene was reported using Bio-Plex 200 system (BioRad Laboratories, Hercules, CA, USA). Probe set information is provided in Additional file 1.
Statistical analysis
Comparisons between groups were performed using Student's t test, Mann-Whitney test or Wilcoxon matched pairs test depending on the experiments. For all analyses, a two-tailed p value ≤0.05 was considered significant. Comparison of variances was performed using the F-test. Statistical analyses were performed using GraphPad Prism version 6.0 (GraphPad Software, San Diego, CA, USA).
Results
DC-10 generation in compliance with clinical-grade manufacturing
The generation of donor-specific Tr1 cells is contingent to the production of donor-derived DC-10 [7] . The first step in defining a clinical-grade compatible protocol was therefore establishing an efficient and reproducible method for DC-10 generation. Based on the MLR/DC-10 protocol used in the ALT-TEN trial [7] , DC-10 were generated from the PBMC adherent fraction in medium supplemented with fetal bovine serum (FBS) in wells. Due to the availability of GMP-compatible human serum (HS) and guidelines from the regulatory authorities on the use of bovine-derived sera (EMEA/CHMP Guideline on the use of bovine serum in the manufacture of human biological medicinal products-original version EMA/ CPMP/BWP/1793/02, and revised version EMA/CHMP/ BWP/457920/2012 rev 1), we compared FBS-and HSsupplemented medium during DC-10 generation. The same batch of FBS was used throughout the experiments described throughout the manuscript. Alongside a certificate of analysis, we confirm the availability of a TSA Certificate of Suitability, issued by EDQM via the process of Certification of Suitability of Monographs of the European Pharmacopoeia. DC-10 recovery was better when medium supplemented with FBS was used, yet the intraexperiment variability-determined by the coefficients of variation (CV)-was high (Fig. 2 ). This high variability could be attributed to the non-specific monocyte selection method, which leads to unpredictable monocyte recovery [9] . Thus, provided methods for clinical-grade monocyte selection are available, monocytes were purified by CD14 + magnetic beads and selected on magnetic columns [10] . DC-10 recovery was less variable upon starting from bead-selected monocytes than from adherence and FBS was necessary to generate sufficient DC-10 numbers (as shown in Fig. 2 and also supported by our unpublished results generated from independent unrelated experiments). DC-10 generated from purified CD14 + monocytes in FBS-supplemented medium had the anticipated phenotype (i.e, CD14 + CD86 + CD16 + ) and they produced IL-10, either at steady state or upon LPS activation ( Fig. 3 ) [7] . Based on these data, we concluded that peripheral blood monocyte selection by CD14 + magnetic beads and culture media supplemented with FBS is the optimal clinical-grade compatible approach for DC-10 generation. This conclusion was drawn based on the limited number of DC-10 generated with HS that was incompatible with the clinical need. In addition, DC-10 will be irradiated and kept in culture with recipient CD4 + T cells for 10 additional days in the absence of any bovine-derived products.
T 10 cell generation in compliance with clinical-grade manufacturing
A protocol for the generation of cell products to be infused into patients has to be solid and highly reproducible to have the highest chance to be used in clinical trials. Accordingly, buffy coats from eight healthy donors were used for DC-10 generation and buffy coats from eight more donors were used for the isolation of CD4 + T cells. Flasks were used as clinical-grade compatible culture containers to generate T 10 cells. Monocytes isolated from buffy coats with lab-grade magnetic columns (AutoMACS-Miltenyi) had a mean purity of 95 ± 3% (mean ± SD). DC-10 yield in flasks (13 ± 6, mean ± SD) was, as expected, lower than that in wells (23 ± 7, mean ± SD) ( Table 1 ) but all DC-10 preparations in flasks had a tolerogenic phenotype (Fig. 3) .
CD4 + T cells isolated from buffy coats with labgrade magnetic columns had a mean purity of 98 ± 1% (mean ± SD). Average T 10 -cell yield after 10 days of co-culture with allogeneic DC-10 was 53 ± 31% (mean ± SD) and T 10 -cell donor-specific anergy was 80 ± 10% (mean ± SD) ( Table 1 ). The T 10 -cell product was constituted of 96 ± 4% (mean ± SD) CD4 + T cells; the remaining non-CD4 + T cells were donor-derived DC-10 cells that were irradiated and therefore dead or prone to die (Additional file 2). Coefficients of variation were high for both DC-10 and T 10 -cell yield, probably due to intrinsic differences among donors. The cut off anergy value for classifying T 10 cells as anergic towards donor antigens was determined utilizing the "mean minus 2× SD" as statistical method [11] . This method was chosen based on our previous experience in the ALT-TEN trial [4] . Based on the eight T 10 -cell preparations generated from eight different donor pairs, the anergy cut off of T 10 cells was 60%. Thus, T 10 -cell products for clinical-grade-compatible use will be considered anergic when the value is ≥60%. Based on our previous murine studies we plan to infuse a total of 2 × 10 6 T 10 cells/kg [12] . Given the DC-10 and T 10cell yield observed, buffy coats would fail to provide sufficient numbers of monocytes and CD4 + T cells to reach the required number of T 10 cells. Up scaling from buffy coats to leukapheresis was therefore a necessary step [13] . As a proof-of-concept, leukapheresis from two healthy donors were used as sources of CD14 + cells for the generation of DC-10 cells. To generate T 10 cells, leukapheresis from two patients with kidney failure on dialysis were used as sources of CD4 + T cells. This setting mimics exactly the clinical situation that we will face during the future clinical trial. The yield of T 10 cells from both donor pairs surpassed the minimum number required for the planned infusions (2 × 10 6 /kg): 11 × 10 6 cells/kg (#001) and 19 × 10 6 cells/ kg (#002). T 10 cells displayed donor-specific anergy higher than 60% (Fig. 4 ). In addition to this, 3 more donor pairs were recruited in the study and T 10 cells were successfully generated from leukapheresis in a GMP-compatible facility (Battaglia et al. manuscript in preparation), further proving protocol up scaling. These data demonstrate that the protocol for the generation of clinical-grade-compatible T 10 cells defined by using buffy coats is also applicable to leukapheresis. Additionally, these data confirm our previous work tailoring the protocol to patients on dialysis [8] . A statistically significant positive correlation existed between the expression of the activation marker CD86 on DC-10 and T 10 -cell yield (Additional file 3). These data suggest that for DC-10 to generate antigen-specific T 10 cells in vitro, they need to have an appropriate level of activation.
In vitro characterization of the medicinal product
Additional important functional features of T 10 cells, that go beyond the development of the clinical-grade-compatible protocol, were also tested to better characterize the cells that will be infused into patients. As we had previously reported, the medicinal products generated in vitro with DC-10 are enriched in Tr1 cells and are comprised not only of Tr1 cells, but also CD4 + memory T cells that respond to nominal antigens [7] . To test the Tr1-cell content in the T 10 cells generated with the clinical-gradecompatible protocol described above, the frequency of CD4 + CD45RA − CD49b + LAG-3 + cells (i.e., Tr1 cells [14] ) was tested by flow cytometry. T 10 cells contained an average of 6 ± 3% (mean ± SD) Tr1 cells, while control Tm cells lacked Tr1 cells (Fig. 5a ). Tr1-cell content in T 10 cells generated from patients on dialysis using leukapheresis products was comparable to that in T 10 cells generated from healthy donors using buffy coats (open versus closed squares, respectively Fig. 5a ). The Tr1-cell content in T 10 cells was irrespective of the frequency of Tr1 cells originally present in the starting CD4 + T-cell population, supporting the notion of de novo generation of donorspecific Tr1 cells rather than the expansion of circulating Tr1 cells (Fig. 5b) .
Treg-cell function is commonly tested in vitro by means of suppression assays [14, 15] . These assays are cumbersome and difficult to be used as standard tests in clinical-grade labs. However, the demonstration that T 10 cells have in vitro suppressive activity further supports their potential efficacy in vivo in patients. The in vitro ability of T 10 cells to suppress proliferation of autologous CD4 + T cells in response to donor-mDC was therefore tested. To prove donor-specific regulation, suppression of autologous CD4 + T cell responses towards third party allogeneic mDC was also tested when numbers of T 10 cells permitted. Priority was given to anergy tests, being most relevant in the upcoming Phase 1 trial testing the safety of T 10 cells. All, except one T 10 -cell preparation, suppressed in vitro proliferation of autologous CD4 + T cells in response to donor-mDC but not to third party-mDC stimulation proving their antigen-specific regulatory properties (Fig. 6a) . Importantly, a positive correlation between Tr1-cell content and the suppressive capacity of T 10 cells was observed thus further suggesting that the in vitro regulation of T 10 cells is mediated by Tr1 cells (Fig. 6b) . Interestingly, a strong correlation was observed when Tr1-cell content exceeded 5% indicating that T 10 cell preparations-to have a good suppressive capacity-need to contain at least 5% of Tr1 cells: CD4 + CD45RA − CD49b + LAG-3 + . To note, one preparation resulted in T 10 cells with no suppressive capacity and low Tr1-cell content. However, the anergy level of these T 10 cells was 84%, suggesting that even with a low Tr1-cell content these cells remain anergic towards donor stimulation, hence complying with the safety requirement of this medicinal product.
A high number of IL-10-producing cells and a low number of IFNγ-producing cells in response to donor-mDC stimulation was detected by dual ELISPOT in T 10 cells, as compared to those detected in control Tm cells (Fig. 7a ). This was confirmed by the levels of IL-10 and IFNγ by ELISA in the supernatant of co-culture of T 10 cells with donor-mDC (Fig. 7b ).
T 10 cells maintained a polyclonal TCR-Vβ repertoire proving lack of a skewed immune response in vitro (Additional file 4) supporting previous findings [4] .
We anticipate the infusion of T 10 cells in patients only upon obtaining all safety data (i.e., quality controls and anergy values) on the medicinal product. Thus, cryopreservation of T 10 cells is inevitable. However, not all cell products are suitable for freezing and thawing, requiring additional manipulation to restore their functionality upon thawing [16, 17] . We thus aimed at testing cell product viability and safety upon various cryopreservation time-points. All T 10 cells had a viability ≥70% upon thawing (after 1, 6 or 12 months of cryopreservation) and preserved their Tr1-cell content (data not shown). All T 10 -cell preparations tested, remained anergic upon donor-mDC stimulation and preserved Tr1 content when thawed (Fig. 8 ). For limited cell number availability, the suppressive ability and/or the cytokine production profile of thawed products could not be tested. We gave priority to the anergy test, given that it provides a clear answer on the safety of thawed medicinal products. These data provide evidence that T 10 cells can be cryopreserved up to 12 months without losing their viability, stability and donor-specific anergy upon thawing and do not require further manipulation prior to in vivo infusion. Similar data were obtained with the 3 GMP-grade generated medicinal products (Battaglia et al. manuscript in preparation). 
Gene signature of circulating Tr1 cells is transiently affected by immunosuppressive drugs
The ONE Study trial with donor-specific Tr1 cells infused into patients undergoing kidney transplantation envisages the concomitant administration of immunosuppressive drugs [5] . Thus, the obvious question on administering cell therapy under active immunosuppression is the effect of the selected drugs on Tr1-cell viability and stability/function in vivo [18] . The ONE Study also included a parallel clinical trial with no cell therapy but standard immunosuppressive treatment, to be used as a reference group for the analysis of cell therapy trials (Additional file 5, detailing immunosuppressive regimen). We aimed at monitoring whether circulating endogenous Tr1 cells preserve their gene signature under standard immunosuppressive therapy: il10 hi , il4 lo , il17 lo , tgfβ hi/int , pd1 hi , granzyme b hi , (reviewed in [1] ). To this aim, circulating Tr1 cells of two patients enrolled in the Reference Group Trial at our clinical site were studied (Additional file 6 detailing immunosuppression dosages and trough levels). The frequency and gene expression profile of circulating Tr1 cells purified from patients after kidney transplant and under active immunosuppression (8, 36 and 60 weeks post-transplant) was compared to those of circulating Tr1 cells purified from the same patients before transplant (4 weeks pre-transplant) and in the absence of any drug treatment. Tr1 cells were detectable in the circulation and were increased in frequency and absolute numbers (Fig. 9a ). Tr1-cell frequency peaked at 8 weeks post-transplant then returned to pre-transplant levels in both patients (Additional file 7). This increase was likely due to homeostatic proliferation after induction therapy, as observed in memory CD4 + T cells (Fig. 9b) [19] . Tr1 cells were isolated by flow cytometry-based cell sorting (Additional file 8 for gating strategy). The gene signature typical of Tr1 cells [14] was slightly diminished (patient #003) or remained unchanged (patient #004) at 8 weeks post-transplant and then returned to pre-transplant levels or heightened at 60 weeks post-transplant (in the two patients, respectively) ( Fig. 9c) .
These data suggest that Tr1 cells expand along with the CD4 + T-cell memory population and that the Tr1cell tolerogenic gene expression profile remains stable even under active immunosuppressive treatment. Data are limited to two patients (being the only patients we enrolled in the reference group trial) but they attempted to dissect the Tr1-cell sensitivity to immunosuppression in vivo, a relevant concern that was-to our knowledge-never addressed before. Importantly, these data suggest that the best timing of ex vivo-generated Tr1cell infusion could be right at the moment of transplant (to reduce inflammation and control alloreactivity) and around 36 weeks post-transplant, when the Tr1-cell signature starts to recover.
Discussion
Optimization of a clinical-grade compatible protocol for generating donor-specific Tr1-enriched cell medicinal products is a pre-requisite for the planned clinical trial in kidney transplant recipients [5] . In this study we described a clinical-grade compatible protocol that enabled the production of donor-specific Tr1-cell enriched medicinal product (named T 10 cells) by coculturing recipient CD4 + T cells with tolerogenic donor DC-10 in the presence of exogenous IL-10 for 10 days. The generated T 10 cells are anergic and suppressive towards donor stimulation in vitro, maintain a stable function upon cryopreservation and are successfully produced in clinically sufficient amounts starting from leukapheresis from patients on dialysis. We also demonstrated that circulating Tr1 cells have a limited sensitivity (in terms of viability and gene expression profile) to standard immunosuppressive treatment in vivo.
Several hurdles are encountered when attempting to perform cell therapy clinical trials [18] . First, the protocol for generating the medicinal product needs to be clinical-grade. To that end, we surpassed all the obstacles. Second, a sufficient number of cells to be infused is a prerequisite. Up scaling to leukapheresis could, in some instances, represent a hurdle in terms of sample collection and protocol adaptability [20] . Here we proved that leukapheresis can be collected with no medical contra-indications from patients on dialysis and that both tolerogenic DC-10 and T 10 cells can be generated from leukapheresis products.
Another key aspect is the definition of lab tests that ensure safety of the cell product. Within The ONE Study consortium, some groups are using polyclonal Tregs. We decided to invest in the donor-specific Tr1-cell-based therapy in an attempt to promote antigen-specific tolerance. However, the generation of T 10 cells with donorderived DC, although they are tolerogenic and well characterized [3, 7] , contains an intrinsic risk of generating alloreactive T cells that, once infused, could be potentially risky for the patient leading to graft rejection. The ONE Study Cell Therapy Trials are feasibility and safety trials [5] . Thus, in vitro assays that prove medicinal-product safety are mandatory. Donor-specific anergy is an optimal assay to test T 10 -cell safety, while the suppression assay provides indications on the possible efficacy of Tr1 cells in vivo. Accordingly, T 10 cells that show no suppressive capacity in vitro but retain donor-specific anergy are considered safe and therefore will be infused in patients participating in The ONE Study cell therapy trial at our institute.
Some groups working with FOXP3 + Tregs as cell therapy products, reported problems with cryopreservation, thus requiring-for instance-further cell manipulation upon thawing [16, 17] . The demonstration that T 10 cells are stable and conserve their Tr1-cell content and donorspecific anergy properties upon cryopreservation, allows for flexibility in their preparation and feasibility for more than one infusion.
Whether infused T 10 cells retain their viability and function in vivo under treatment with immunosuppressive drugs remains an important open question. One approach to address this issue was by testing the effect of immunosuppressive drugs in vitro on the ex vivoexpanded human FOXP3 + Tregs or by using humanized mouse models [21] . This showed detrimental dose-dependent effects of immunosuppressive treatments on viability and proliferative capacity while sparing the immunosuppressive function of FOXP3 + Tregs. We approached this issue by analyzing the frequency and the gene signature of circulating Tr1 cells collected from renal transplant recipients under active immunosuppressive treatment. Our data suggest that immunosuppressive drugs do not affect Tr1 cells since the cells remain in circulation and a transient change in the intensity of the gene signature is observed. Based on these data, we chose two different timings of T 10 -cell infusion to increase the chance of obtaining in vivo immune regulation. The first dose will be infused at the time of transplant (for Tr1cell enrichment just around the transplant period). The second dose will be infused at 36 weeks post-transplant, timepoint in which the Tr1-cell signature is recovering.
Taken together, our results demonstrate the reproducibility of an optimized clinical-grade-compatible protocol for generating Tr1-enriched T 10 cells. The necessary following steps for performing the trial in patients are underway.
Conclusion
We describe the steps undertaken to achieve and validate a reproducible optimized clinical-grade compatible protocol capable of generating donor-specific Tr1 cells in sufficient numbers. Additionally, selecting the timing of infusion of Tr1 cells to patients under immunosuppression remains an open question. We provide data assessing the viability and gene signature of circulating Tr1 cells in the presence of active immunosuppression thus supporting our rationale for selecting the timing of the planned infusions. We believe that this study highlights the importance of optimizing and validating Tr1 cell manufacturing protocols to bring them closer to the bedside.
